Please assess the completion status of the following clinical trial:

Trial Title: Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* •Adult female-16 years to 35 years of age who have been diagnosed with PCOS desiring contraception~  * Actual BMI \>18 to \<35kg/ m2~ * Written consent for participation in the study~ * Patient completed lactation~Exclusion Criteria:~* Metabolic abnormalities requiring pharmacological intervention (except controlled thyroid disease)~  * Uncontrolled hypertension~ * Cancer or history of hormone-dependent cancer~ * History of cholestasis~ * Presence of contradictions for OC administration~ * Personal history of cardiovascular events.~ * Use of drugs known to exacerbate glucose tolerance.~ * No prescription or over-the-counter weight-loss drugs~ * Diabetes~ * Use of medications that affect blood pressure or lipid profile~ * Smoking in past 6 months~ * Known thrombogenic mutations (e.g. Factor V Leiden)~ * Current or history of deep venous thrombosis/pulmonary embolism~ * Major surgery with prolonged immobilization~ * Injectable hormonal contraceptive use within 6 months~ * Use of hormonal (e.g., oral contraceptive \[OC\] pill) or insulin-sensitizing medication unless willing to cease medications for 3 months before study measurements

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- 3 mg DRSP/20 μg EE--normal weight (Type: EXPERIMENTAL): Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~Normal weight -BMI 18-24.9 kg/ m2
- 3 mg DRSP/20 μg EE- Overweight (Type: EXPERIMENTAL): Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~BMI 25-29.9 kg/ m2
- 3 mg DRSP/20 μg EE- Grade 1 obese (Type: EXPERIMENTAL): Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~BMI 30-34.9 kg/ m2

Based on this trial design, predict the completion outcome and termination type (if applicable).